## Edgar Filing: INTEGRATED BIOPHARMA INC - Form 8-K

## INTEGRATED BIOPHARMA INC

Form 8-K August 13, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2004

Integrated BioPharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware 000-28876 22-2407475

(State or other jurisdiction of (Commission File Number) (IRS Employer incorporation or organization) Identification No.)

225 Long Avenue

Hillside, New Jersey
07205
----(Address of principal executive offices)
(Zip Code)

Registrant's telephone number, including area code: (973) 926-0816

 $\label{eq:Not Applicable} \end{substitute} \begin{substitute} \begin$ 

Item 5. Other Events and Regulation FD Disclosure.

On August 13, 2004, Integrated BioPharma, Inc., a Delaware corporation (the "Company"), issued a press release stating that it knows of no fundamental reason for the recent decline of its stock price. The press release is attached as an exhibit to this Report.

- Item 7. Financial Statements and Exhibits
- (c) Exhibits.

## Edgar Filing: INTEGRATED BIOPHARMA INC - Form 8-K

Exhibit No. Description

99.1 Press Release issued by Integrated BioPharma, Inc. on

August 13, 2004

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 13, 2004 INTEGRATED BIOPHARMA, INC.

By: /s/ Eric Friedman

Eric Friedman

Vice President and Chief Financial Officer

Exhibit Index

Exhibit No. Description

99.1 Press Release issued by Integrated BioPharma, Inc. on

August 13, 2004